

**Table 1: Use of short-acting β-agonists and inhaled corticosteroids in 1995 by British Columbia patients 5–50 years of age**

Use of β-agonist, no. of canisters/yr	Use of inhaled corticosteroid, µg/d; no. (and %*) of patients						Total
	≤ 100	101–200	201–399	400–800	> 800		
≤ 4	11 919 (49.7)	1430 (6.0)	671 (2.8)	3033 (12.6)	1638 (6.8)	18 691 (77.9)	
5–8	808 (3.4)	205 (0.9)	176 (0.7)	406 (1.7)	631 (2.6)	2226 (9.3)	
9–12	345 (1.4)	90 (0.4)	88 (0.4)	206 (0.8)	442 (1.8)	1171 (4.9)	
13–20	248 (1.0)	89 (0.4)	89 (0.4)	207 (0.9)	380 (1.6)	1013 (4.2)	
> 20	170 (0.7)	82 (0.3)	91 (0.4)	205 (0.8)	337 (1.4)	885 (3.7)	
Total	13 490 (56.2)	1896 (7.9)	1115 (4.6)	4057 (16.9)	3428 (14.3)	23 986 (100.0)	

\*Percentages are calculated with reference to the total number of patients in the study (23 986).

[Return to text]